Novel non-transplant treatment approaches for high-risk TP53-mutated myeloid disease скачать в хорошем качестве

Novel non-transplant treatment approaches for high-risk TP53-mutated myeloid disease

Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, discusses novel approaches for treating high-risk TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This patient population represents a significant unmet need in malignant hematology, and Prof. Konopleva outlines various efforts that have been made to develop novel therapeutic strategies to improve survival outcomes. Although much of the current work is still preclinical, Prof. Konopleva hopes there will be an option to enroll more patients into clinical trials to decide on the next steps in this patient population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.